New Trial Data Continue to Support DPX-Survivac in Treating Advanced Ovarian Cancer

New Trial Data Continue to Support DPX-Survivac in Treating Advanced Ovarian Cancer
Immune responses in women with advanced ovarian cancer  being treated with DPX-Survivac in clinical trials continue to support the immunotherapy's potential, alone or in combination, to be effective in this patient population. DPX-Survivac, developed by IMV, is being seen to elicit significant anti-tumor responses in these ovarian cancer patients. It works by inducing strong and sustained survivin-specific immune T-cells, and increasing the infiltration of such cells into tumors. These findings were highlighted in the poster, "DPX-Survivac, a novel T-cell immunotherapy, to induce robust T-cell responses in advanced ovarian cancer," presented at the ASCO-SITC Clinical Immuno-Oncology Symposium, held on Feb. 6-8 in Orlando. Results were presented by Oliver Dorigo, MD, PhD, a professor of Obstetrics and Gynecology at Stanford University Medical Center. "These translational data continue to validate the mechanism of action of our lead program in advanced ovarian cancer," Frederic Ors, president, and CEO at IMV, said in a press release. "We continue to believe DPX-Survivac may offer significant clinical utility and a potentially meaningful treatment option for patients in this setting, as well as in other hard-to-treat indications in which surviv
Subscribe or to access all post and page content.